Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Reiter A, George TI, Engelbrecht ME, et al.

Nat Med · 2021

Grade Acohortn=86
DOI ↗

Key Findings

  • ●EXPLORER phase 1: avapritinib safety and dose-finding in AdvSM
  • ●Established recommended phase 2 dose

Referenced in (1 disease)

Systemic Mastocytosis
ID: doi-10-1038-s41591-021-01538-9DOI: 10.1038/s41591-021-01538-9